Free tool
FAERS Monitor: Trelegy Ellipta
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 209482 or its brand name (Trelegy Ellipta, Fluticasone Furoate, Umeclidinium Bromide, Vilanterol Trifenatate). Reports on generic versions are filed under their own applications.
Reports
43,081
Serious
17,505
41% of reports
Hospitalization
8,710
Death reported
3,373
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea6,025
- drug ineffective3,674
- product dose omission issue3,485
- wrong technique in device usage process3,401
- product complaint3,063
- cough3,012
- death2,401
- pneumonia2,203
- asthma1,886
- chronic obstructive pulmonary disease1,648
- fatigue1,468
- off label use1,436
- product use in unapproved indication1,422
- headache1,420
- dysphonia1,190
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 6 |
| 2017 | 21 |
| 2018 | 1,227 |
| 2019 | 3,883 |
| 2020 | 3,782 |
| 2021 | 4,331 |
| 2022 | 4,768 |
| 2023 | 5,640 |
| 2024 | 6,970 |
| 2025 | 7,120 |
| 2026 | 5,332 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,011,078 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product complaintSignal | 3,063 | 67.0 | 64.6 | 175,208 |
| wrong technique in device usage processSignal | 3,401 | 38.3 | 37.0 | 114,648 |
| chronic obstructive pulmonary diseaseSignal | 1,648 | 15.9 | 15.1 | 22,309 |
| dysphoniaSignal | 1,190 | 10.1 | 9.6 | 9,597 |
| asthmaSignal | 1,886 | 8.3 | 7.9 | 11,907 |
| product dose omission issueSignal | 3,485 | 5.8 | 5.7 | 14,016 |
| coughSignal | 3,012 | 5.3 | 5.1 | 10,501 |
| dyspnoeaSignal | 6,025 | 5.2 | 5.1 | 21,020 |
| pneumoniaSignal | 2,203 | 3.3 | 3.2 | 3,637 |
| product use in unapproved indicationSignal | 1,422 | 2.8 | 2.7 | 1,668 |
| drug ineffective | 3,674 | 1.4 | 1.3 | 376 |
| death | 2,401 | 1.4 | 1.3 | 239 |
| headache | 1,420 | 1.1 | 1.1 | 15 |
| fatigue | 1,468 | 0.9 | 0.9 | 10 |
| off label use | 1,436 | 0.8 | 0.8 | 74 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.